CD47 inhibitors work by blocking the CD47-SIRPα signaling axis, effectively releasing tumor cells from immune evasion by macrophages, activating macrophage phagocytic function, and thereby enhancing the body’s anti-tumor immune response. The gene discussed is SIRPA; the disease is neoplasm.